GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (NAS:RCKT) » Definitions » Quick Ratio

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Quick Ratio : 7.80 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Rocket Pharmaceuticals's quick ratio for the quarter that ended in Dec. 2023 was 7.80.

Rocket Pharmaceuticals has a quick ratio of 7.80. It generally indicates good short-term financial strength.

The historical rank and industry rank for Rocket Pharmaceuticals's Quick Ratio or its related term are showing as below:

RCKT' s Quick Ratio Range Over the Past 10 Years
Min: 0.51   Med: 15.88   Max: 27.13
Current: 7.8

During the past 12 years, Rocket Pharmaceuticals's highest Quick Ratio was 27.13. The lowest was 0.51. And the median was 15.88.

RCKT's Quick Ratio is ranked better than
75.56% of 1551 companies
in the Biotechnology industry
Industry Median: 3.51 vs RCKT: 7.80

Rocket Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Rocket Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals Quick Ratio Chart

Rocket Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.81 14.94 17.69 9.29 7.80

Rocket Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.29 10.83 9.09 13.35 7.80

Competitive Comparison of Rocket Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Rocket Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rocket Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Quick Ratio falls into.



Rocket Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Rocket Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(378.222-0)/48.505
=7.80

Rocket Pharmaceuticals's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(378.222-0)/48.505
=7.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rocket Pharmaceuticals  (NAS:RCKT) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Rocket Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rocket Pharmaceuticals (Rocket Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Executives
John Militello officer: See Remarks C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Gotham Makker director 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Gaurav Shah director, officer: See Remarks 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Kinnari Patel officer: Chief Operating Officer 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Mark Andrew White officer: Chief Medical Officer C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512
Jonathan David Schwartz officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fady Ibraham Malik director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Martin Wilson officer: General Counsel C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Carlos Garcia-parada officer: Chief Financial Officer C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118
Elisabeth Bjork director C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116
Kamran Alam officer: SVP - Finance & PFO 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
David P Southwell director, officer: See Remarks C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Naveen Yalamanchi director 412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019
Brian Batchelder officer: See Remarks 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Headlines

From GuruFocus

Should Investors Worry About Rocket Pharmaceuticals Inc's Insider Sells?

By GuruFocus Research GuruFocus Editor 05-20-2023